Tnf News

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion technology, which is designed to extend the circulating half-life of proteins and peptides.

Patients with rheumatoid arthritis with synovial lymphocyte aggregates respond better to the anti-tumor necrosis factor agent infliximab than those with only diffuse leukocyte infiltration, researchers from the Netherlands report.

Although Stelara is entering a crowded treatment room for psoriasis, this first-in-class interleukin inhibitor could put the "no more tears" back in J&J's future - if successfully marketed to specialists, in particular dermatologists, as it is a novel and less cumbersome injectable than established biologics for psoriasis, the tumor necrosis ...

TRAF2-MLK3 interaction is essential for TNF- -induced MLK3 activation 1Department of Pharmacology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA 2Division of Molecular Cardiology, The Texas A&M University System Health Science Center, College of Medicine, Temple, TX 76504, USA 3Department of Medicine, Division of ...

WALTHAM,A Mass. Biotech companies that manufacture a class of drugs used to treat autoimmune disorders stand to lose more than $9 billion in Europe and the United States by 2018 thanks to competition from biosimilars, according to a report.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, for the treatment of rheumatoid arthritis following the agent's expected launch in 2010.

A Swedish study has concluded that rheumatoid arthritis patients did not experience an increased cancer risk in the first 6 years of treatment with TNF blockers .

During the past decade, a new class of drugs, called TNF inhibitors, has improved the lives of tens of thousands of people who suffer from painful autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.

Treatment with tumor necrosis factor blockers doesn't increase rheumatoid arthritis patients' risk of cancer, new research has found.

A recent study by Swedish researchers found that rheumatoid arthritis patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor therapy.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, ...

Cephalon, Inc. and BioAssets Development Corporation , a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor -alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established ...

Main Category: Arthritis / Rheumatology Also Included In: Clinical Trials / Drug Trials Article Date: 23 Oct 2009 Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor -alpha inhibitors will continue to dominate first- and second-line biologic ...

For many people with rheumatoid arthritis , the traditional, and much cheaper, disease-modifying antirheumatic drugs appear to work just as well as newer TNF blockers that target the underlying disease process, a large study shows.

Children who once faced lifelong disabilities from arthritis seem to be getting relief from powerful but costly new medicines, according to studies presented in Philadelphia this week.

Oct 19, 2009 - Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data from studies of IMO-3100 in combination with Enbrel in a mouse model of arthritis.

People who take immune-disease drugs called TNF blockers for rheumatoid arthritis should check their bodies regularly for abnormal growths that can signal skin cancer .

National report - Experts disagree on the possible impact a new pediatric cancer warning for tumor necrosis factor inhibitors may have on this drug category's growth.

National report - Although hardly unexpected, the Food and Drug Administration's decision to add a warning about a possible link between tumor necrosis factor antagonists and cancer in children goes too far, say most dermatologists contacted by Dermatology Times .